GI CANCERS

New research shows T-cell receptor sequencing can reveal immune signatures of precancer and cancer in Lynch syndrome carriers, aiding early detection.

Dostarlimab previously received breakthrough therapy designation from the FDA for dMMR/MSI-H rectal cancer.

This is the third complete response letter the FDA has issued for rivoceranib plus camrelizumab for hepatocellular carcinoma.

The results jeopardize the accelerated approval of adagrasib plus cetuximab for KRAS G12C–mutated mCRC.

FDA issues Complete Response Letter for manganese chloride tetrahydrate (Orviglance), an oral liver MRI contrast agent for renal-impaired patients.

Building on these data, the ongoing phase 3 BATTMAN trial is exploring botensilimab plus balstilimab in refractory MSS mCRC.

The zoldonrasib data build on the recent historical breakthrough with daraxonrasib in PDAC.

During a live event, Zev Wainberg, MD, and participants discussed frontline immunotherapy selection in advanced HER2-negative gastrointestinal cancers.

Explore how GI and pancreatic NET sites shape symptoms and survival, plus NCCN-backed therapies from somatostatin analogs to PRRT and cabozantinib.

FDA issues CRL for Ga-68 edotreotide NET PET kit, citing third-party manufacturing; decentralized SSTR imaging promise remains pending.

It was previously shown that the STELLAR-303 trial achieved the coprimary end point of OS in the ITT population.

Blood-based T‑cell receptor sequencing reveals immune “fingerprints” in Lynch syndrome, helping track precancers early and paving the way for new cancer surveillance biomarkers.

The supplemental biologics license application is supported by the phase 3 ATOMIC trial.

FDA clears automated PD-L1 22C3 testing on Dako Omnis for 4 more tumors, streamlining labs and guiding Keytruda therapy decisions.

Dr Pant highlights phase 3 data showing oral daraxonrasib nearly doubles overall survival vs chemotherapy in metastatic pancreatic cancer.

"These findings may be considered practice changing for medical oncologists treating HCC globally,” said Vishwanath Sathyanarayanan, MD.

FDA opens expanded access to daraxonrasib for metastatic pancreatic cancer, as phase 3 data boost survival and clinics race to manage access hurdles.

The FDA has granted suplexa, a non-engineered autologous cellular immunotherapy, fast track designation for patients with MSI-H colorectal cancer.

During a live event, Ronan J. Kelly, MD, MBA, and participants discussed how they use PD-1 inhibitors in patients with upper gastrointestinal cancers.

The DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan has elicited antitumor activity across subtypes of extrapulmonary neuroendocrine carcinomas.

The FDA has approvesd zenocutuzumab-zbco for previously treated NRG1 fusion–positive cholangiocarcinoma cholangiocarcinoma.

The FDA previously granted RZ-001 both orphan drug designation and fast track designation for hepatocellular carcinoma.

The phase 1/2 data led to the phase 3 RASolute 302 trial which supported the FDA's allowance of early access to daraxonrasib in PDAC.

Shagufta Shaheen, MD, discusses treatment strategies for pancreatic NETs.

Pelareorep plus FOLFIRI and bevacizumab showed durable responses in second-line RAS-mutant MSS metastatic colorectal cancer.